Obstetrics and Gynecology

Michael J. Goodheart, MD

Portrait

Assistant Professor of Obstetrics and Gynecology  - Gynecologic Oncology
Assistant Professor of Anatomy and Cell Biology

Contact Information

Primary Office: 31508 PFP
200 Hawkins Dr
Iowa City, IA 52242
Primary Office Phone: 319-356-2015

Email: michael-goodheart@uiowa.edu

Education

BA, Chemistry, North Carolina State University, Raleigh, North Carolina
BS, North Carolina State University, Raleigh, North Carolina
MD, Medicine, East Carolina State University School of Medicine, Greenville, North Carolina

Residency, Obstetrics and Gynecology, Louisiana State University School of Medicine, New Orleans, Louisiana
Residency, Surgery, University of South Florida School of Medicine, Tampa, Florida
Fellowship, Gynecologic Oncology, University of Iowa Children's Hospital, Iowa City, Iowa
Fellowship, Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa

Licensure and Certifications

Gynecologic Oncology
General Obstetrics and Gynecology
Iowa Medical License, #33538

Research Summary

Relating p53 mutation types to angiogenesis and immunohistochemical expression in epithelial ovarian cancers, and mutations of the BRCA2 gene in ovarian cancers.

Transcriptional regulation of the lymphoid enhancer factor-1 (Lef-1) promoter and its relevance in the pathogenesis of ovarian and endometrial cancer.

All Publications

Brachova P, Mueting S, Carlson M, Goodheart M, Button A, Mott S, Dai D, Thiel K, Devor E, Leslie K.  TP53 oncomorphic mutations predict resistence to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma [Epub ahead of print].  Int J Oncol.  2014 November 11. 

Zhang Z, Kim K, Li X, Moreno M, Sharp T, Goodheart M, Safe S, Dupuy A, Amendt B.  MicroRNA-26b Represses Colon Cancer Cell Proliferation by Inhibiting Lymphoid Enhancer Factor 1 (LEF-1) Expression.  Mol Cancer Ther [Epub ahead of print].  2014 April 30. 

Stephan J, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, Reyes H, Button A, Goodheart M.  Intra-operative frozen section results reliably predict final pathology in endometrial cancer..  Gynecol Oncol. .  2014 April 1. 

Devor E, Reyes H, Santillan D, Santillan M, Onukwugha C, Goodheart M, Leslie K.  Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions..  Obstet Gynecol Int..  2014 March 17. 2014:5 pages.

Nadkarni N, Geest K, Neff T, Young B, Bender D, Ahmed A, Smith B, Button A, Goodheart M.  Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer..  Cancer letters.  2013 April. 331(1):99-104.
[PubMed]

Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart M, Dahmoush L, Penedo F, Lucci J, Ganjei-Azar P, Mendez L, Markon K, Lubaroff D, Thaker P, Slavich G, Sood A, Lutgendorf S.  Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability..  Brain, behavior, and immunity.  2013 March. 30 Suppl:S126-34.
[PubMed]

Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart M, Penedo F, Lubaroff D, Sood A, Lutgendorf S.  Sleep disturbance, cytokines, and fatigue in women with ovarian cancer..  Brain, behavior, and immunity.  2012 October. 26(7):1037-44.
[PubMed]

Engle D, Connor J, Morris P, Bender D, De Geest K, Ahmed A, Goodheart M.  Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial..  Archives of gynecology and obstetrics.  2012 September. 286(3):717-21.
[PubMed]

Abu-Hejleh T, Mezhir J, Goodheart M, Halfdanarson T.  Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers..  Current oncology reports.  2012 August. 14(4):277-84.
[PubMed]

Lutgendorf S, De Geest K, Bender D, Ahmed A, Goodheart M, Dahmoush L, Zimmerman M, Penedo F, Lucci J, Ganjei-Azar P, Thaker P, Mendez L, Lubaroff D, Slavich G, Cole S, Sood A.  Social influences on clinical outcomes of patients with ovarian cancer..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  2012 August. 30(23):2885-90.
[PubMed]

Shelton D, Fornalik H, Neff T, Park S, Bender D, DeGeest K, Liu X, Xie W, Meyerholz D, Engelhardt J, Goodheart M.  The role of LEF1 in endometrial gland formation and carcinogenesis..  PloS one.  2012 July 6. 7(7):e40312.
[PubMed]

Leslie K, Thiel K, Goodheart M, DeGeest K, Jia Y, Yang S.  Endometrial cancer..  Obstet Gynecol Clin North Am.  2012 June. 39(2):255-68.

Leslie K, Thiel K, Goodheart M, De Geest K, Jia Y, Yang S.  Endometrial cancer..  Obstetrics and gynecology clinics of North America.  2012 June. 39(2):255-68.
[PubMed]

Devor E, DE Mik J, Ramachandran S, Goodheart M, Leslie K.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma..  Experimental and therapeutic medicine.  2012 April. 3(4):677-682.
[PubMed]

Fornalik H, Goodheart M, Buekers T, De Geest K, Jacobson G.  Aspirin and Warfarin are associated with Improved Overall Survival in Medically Inoperable Endometrial Cancer Patients Treated with Radiation Therapy..  Gynecology & Obstetrics S4:002.  2012 January 25. 
[Link]

Shamshirsaz A, Buekers T, Degeest K, Bender D, Zamba G, Goodheart M.  A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival..  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.  2011 October. 21(7):1232-40.
[PubMed]

Devor E, Hovey A, Goodheart M, Ramachandran S, Leslie K.  microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs..  Oncology reports.  2011 October. 26(4):995-1002.
[PubMed]

Xie W, Fisher J, Lynch T, Luo M, Evans T, Neff T, Zhou W, Zhang Y, Ou Y, Bunnett N, Russo A, Goodheart M, Parekh K, Liu X, Engelhardt J.  CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice..  The Journal of clinical investigation.  2011 August. 121(8):3144-58.
[PubMed]

Zhang Z, Liu X, Wu T, Liu J, Zhang X, Yang X, Goodheart M, Engelhardt J, Wang Y.  Selective suppression of cervical cancer Hela cells by 2-O-β-D-glucopyranosyl-L-ascorbic acid isolated from the fruit of Lycium barbarum L..  Cell biology and toxicology.  2011 April. 27(2):107-21.
[PubMed]

Lutgendorf S, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers T, Mendez L, Krueger G, Clevenger L, Lubaroff D, Sood A, Cole S.  Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients..  Brain, behavior, and immunity.  2011 February. 25(2):250-5.
[PubMed]

Lutgendorf S, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers T, Goodheart M, Antoni M, Sood A, Lubaroff D.  Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach..  Brain, behavior, and immunity.  2010 November. 24(8):1231-40.
[PubMed]

Liu X, Luo M, Xie W, Wells J, Goodheart M, Engelhardt J.  Sox17 modulates Wnt3A/beta-catenin-mediated transcriptional activation of the Lef-1 promoter..  American journal of physiology. Lung cellular and molecular physiology.  2010 November. 299(5):L694-710.
[PubMed]

Steines J, Larson J, Wilkinson N, Kirby P, Goodheart M.  Intestinal lymphangiectasia mimicking primary peritoneal carcinoma..  American journal of obstetrics and gynecology.  2010 October. 203(4):e9-e11.
[PubMed]

Petersen E, Shamshirsaz A, Brennan T, Demetroulis E, Goodheart M.  Malignant pericardial effusion with cardiac tamponade in ovarian adenocarcinoma..  Archives of gynecology and obstetrics.  2009 October. 280(4):675-8.
[PubMed]

Goodheart M, Rose S, Hattermann-Zogg M, Smith B, De Young B, Buller R.  BRCA2 alteration is important in clear cell carcinoma of the ovary..  Clinical genetics.  2009 August. 76(2):161-7.
[PubMed]

Jacobson G, Lammli J, Zamba G, Hua L, Goodheart M.  Thromboembolic events in patients with cervical carcinoma: Incidence and effect on survival..  Gynecologic oncology.  2009 May. 113(2):240-4.
[PubMed]

Lutgendorf S, DeGeest K, Sung C, Arevalo J, Penedo F, Lucci J, Goodheart M, Lubaroff D, Farley D, Sood A, Cole S.  Depression, social support, and beta-adrenergic transcription control in human ovarian cancer..  Brain, behavior, and immunity.  2009 February. 23(2):176-83.
[PubMed]

Soper S, van der Heijden G, Hardiman T, Goodheart M, Martin S, de Boer P, Bortvin A.  Mouse maelstrom, a component of nuage, is essential for spermatogenesis and transposon repression in meiosis..  Developmental cell.  2008 August. 15(2):285-97.
[PubMed]

Goodheart M, Jacobson G, Smith B, Zhou L.  Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity..  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.  2008 January. 18(1):95-103.
[PubMed]

Driskell R, Goodheart M, Neff T, Liu X, Luo M, Moothart C, Sigmund C, Hosokawa R, Chai Y, Engelhardt J.  Wnt3a regulates Lef-1 expression during airway submucosal gland morphogenesis..  Developmental biology.  2007 May. 305(1):90-102.
[PubMed]

Cheng Y, Buffone M, Kouadio M, Goodheart M, Page D, Gerton G, Davidson I, Wang P.  Abnormal sperm in mice lacking the Taf7l gene..  Molecular and cellular biology.  2007 April. 27(7):2582-9.
[PubMed]

Baltus A, Menke D, Hu Y, Goodheart M, Carpenter A, de Rooij D, Page D.  In germ cells of mouse embryonic ovaries, the decision to enter meiosis precedes premeiotic DNA replication..  Nature genetics.  2006 December. 38(12):1430-4.
[PubMed]

Pan J, Goodheart M, Chuma S, Nakatsuji N, Page D, Wang P.  RNF17, a component of the mammalian germ cell nuage, is essential for spermiogenesis..  Development (Cambridge, England).  2005 September. 132(18):4029-39.
[PubMed]

Goodheart M, Ritchie J, Rose S, Fruehauf J, De Young B, Buller R.  The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer..  Clinical cancer research : an official journal of the American Association for Cancer Research.  2005 May. 11(10):3733-42.
[PubMed]

Jacobson G, Kamath R, Smith B, Goodheart M.  Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer..  Gynecologic oncology.  2005 February. 96(2):470-4.
[PubMed]

Bortvin A, Goodheart M, Liao M, Page D.  Dppa3 / Pgc7 / stella is a maternal factor and is not required for germ cell specification in mice..  BMC developmental biology.  2004 February. 4:2.
[PubMed]

Geisler J, Goodheart M, Sood A, Holmes R, Hattermann-Zogg M, Buller R.  Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma..  Cancer.  2003 November. 98(10):2199-206.
[PubMed]

Rose S, Robertson A, Goodheart M, Smith B, DeYoung B, Buller R.  The impact of p53 protein core domain structural alteration on ovarian cancer survival..  Clinical cancer research : an official journal of the American Association for Cancer Research.  2003 September. 9(11):4139-44.
[PubMed]

Stone P, Goodheart M, Rose S, Smith B, DeYoung B, Buller R.  The influence of microvessel density on ovarian carcinogenesis..  Gynecologic oncology.  2003 September. 90(3):566-71.
[PubMed]

Rose S, Goodheart M, DeYoung B, Smith B, Buller R.  p21 expression predicts outcome in p53-null ovarian carcinoma..  Clinical cancer research : an official journal of the American Association for Cancer Research.  2003 March. 9(3):1028-32.
[PubMed]

Goodheart M, Rose S, Hattermann-Zogg M, Smith B, DeYoung B, Sorosky J, Buller R.  BRCA2 Alteration is important in clear cell carcinoma of the ovary.  Mid-Atlantic Gynecologic Oncologic Society, Durham, North Carolina.  2003. 

Goodheart M, Rose S, Fruehauf J, Smith B, Anderson B, Buller R.  The relationship of Thrombospondin-1 to risk factors in ovarian carcinoma.  Western Association of Gynecologic Oncologists, Steamboat Springs, Colorado.  2003. 

Goodheart M, Vasef M, Sood A, Davis C, Buller R.  Ovarian cancer p53 mutation is associated with tumor microvessel density..  Gynecologic oncology.  2002 July. 86(1):85-90.
[PubMed]

Goodheart M, Sood A, Kirby P, Davis C, Buller R.  Ovarian cancer VEGF staining is independent of p53 mutation. .  American Association of Cancer Research, New Orleans, Louisiana.  2001. 

Goodheart M, Sood A, Vasef M, Davis C, Buller R.  Ovarian cancer p53 mutations are associated with increased microvessel density.  Society of Gynecologic Oncologists, Nashville, Tennessee.  2000. 

Goodheart M, Rose S, DeYoung B, Richie J, Buller R.  The relationship of molecular markers of p53 function and angiogenesis to prognosis of Stage I epithelial ovarian cancer.  Society of Gynecologic Oncologists, Miami Beach, Florida.. 

Date Last Modified: 06/07/2014 - 21:56:23